Phase II study of dasatinib (BMS-354825) in patients with metastatic adenocarcinoma of the pancreas

Oncologist

Volumn 18, Issue 10, 2013, Pages 1091-1092

  Chee, Cheng Ean ^a   Krishnamurthi, Smitha ^a   Nock, Charles J ^a   Meropol, Neal J ^a   Gibbons, Joseph ^a   Fu, PingFu ^a   Bokar, Joseph ^a   Teston, Lois ^a   O'Brien, Timothy ^b   Gudena, Vinay ^a   Reese, Amy ^a   Bergman, Mark ^a   Saltzman, Joel ^a   Wright, John J ^c   Dowlati, Afshin ^a   Brell, Joanna ^c  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b METROHEALTH MEDICAL CENTER   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DASATINIB; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; THIAZOLE DERIVATIVE;

ARTICLE; CIRCULATING TUMOR CELL; DRUG DOSE REDUCTION; EDEMA; FATIGUE; FLUID RETENTION; HUMAN; MAJOR CLINICAL STUDY; NAUSEA; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SIDE EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; ADENOCARCINOMA; ADVERSE DRUG REACTION; CLINICAL TRIAL; DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; NEOPLASM METASTASIS; PANCREATIC NEOPLASMS; PATHOLOGY; TUMOR EMBOLISM;

ADENOCARCINOMA; DISEASE-FREE SURVIVAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; KAPLAN-MEIER ESTIMATE; NEOPLASM METASTASIS; NEOPLASTIC CELLS, CIRCULATING; PANCREATIC NEOPLASMS; PROTEIN KINASE INHIBITORS; PYRIMIDINES; THIAZOLES;

EID: 84886059624     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2013-0255     Document Type: Article

References (0)